About
ALP AI is a biotech startup building an AI-driven platform to de-risk and improve antibody drug candidates by predicting and reducing immunogenicity / Anti-Drug Antibody (ADA) responses.
The core idea is a closed-loop system:
-
Generative AI / protein language models propose sequence improvements (reduce ADA risk without hurting efficacy)
-
A human immune validation layer using tonsil-derived immune organoids tests real immune reactivity
-
Results feed back into the models to continuously improve prediction and design quality
ALP AI aims to become a key “immunogenicity infrastructure” partner for biologics R&D, supporting biotech and pharma teams in early-stage selection + antibody re-engineering to avoid failures later in clinical development.
Target Markets of your organization / Expansion or target markets of your spin-off
SwitzerlandUSEMEA
Covered funding stages of your organization / Spin-off Funding Stage
Pre-Seed
Industry Sector your organization invests in / Industry Sector of your Spin-off
Bio Tech